Provectus extends automatic conversion date for Series D and D-1 preferred stock to Dec 2028

PROVECTUS BIOPHARMACEUTICALS, INC.

Automatic conversion date for Series D and D-1 preferred stock extended from June 20, 2026 to December 31, 2028.
Amendments apply to Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, both par value $0.001.
Board of directors and a special committee of independent directors approved the amendments.
No changes to conversion terms other than the extension of the conversion date.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PROVECTUS BIOPHARMACEUTICALS, INC.: Extended the automatic conversion date of Series D and Series D-1 Convertible Preferred Stock from June 20, 2026 to December 31, 2028 (effective 2026-01-30).

Change: charter amendment
Effective: 2026-01-30

Exact text from the filing

On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.

View on SEC.gov

Browse all governance changes →

PROVECTUS BIOPHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-004730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.